The World Health Organization (WHO) has recommended the use of Ervebo, a vaccine developed by Merck, for the prevention of Ebola virus disease in the Democratic Republic of Congo (DRC). This recommendation comes as childhood deaths from the disease continue to rise in the region, according to a new report released by the WHO Technical Advisory Group on candidate vaccine prioritisation for Bundibugyo virus disease. The group’s findings, published on Friday, highlight the potential of Ervebo to curb the spread of the virus, particularly among vulnerable populations.
The DRC has been grappling with multiple Ebola outbreaks in recent years, with the latest one emerging in the North Kivu province. Health officials have expressed cautious optimism about the vaccine’s effectiveness, though challenges remain in ensuring widespread distribution and public trust. Ervebo was previously used during the 2018-2020 Ebola outbreak in the DRC, where it showed promising results in reducing mortality rates.
The WHO’s endorsement of Ervebo is seen as a critical step in the ongoing efforts to control the outbreak. However, logistical hurdles and community resistance continue to pose significant obstacles. Health workers are now working closely with local leaders to improve vaccine uptake and address misinformation. The situation remains under close monitoring by international health organizations.
